Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).

被引：0
|
作者：
Mohr, Peter
Hauschild, Axel
Trefzer, Uwe
Enk, Alexander
Tilgen, Wolfgang
Loquai, Carmen
Gogas, Helen
Haalck, Thomas
Koller, Josef
Schadendorf, Dirk
Dummer, Reinhard
Gutzmer, Ralf
Brockmeyer, Norbert
Hoelzle, Erhard
Sunderkoetter, Cord
Mauch, Cornelia
Stein, Anette
Schneider, Lars
Podda, Maurizio
Weichenthal, Michael
机构：
[1] Elbe Klinikum Buxtehude, Buxtehude, Germany
[2] Univ Klinikum Schleswig Holstein, Kiel Schleswig Holstein, Germany
[3] Charite, Melanomactr, D-13353 Berlin, Germany
[4] Heidelberg Univ, Hautklin, Heidelberg, Germany
[5] Univ Dept Dermatol, Homburg, Germany
[6] Univ Dept Dermatol, Mainz, Germany
[7] Hellen Cooperat Oncol Grp, Athens, Greece
[8] Univ Dept Dermatol, Hamburg, Germany
[9] Landesklin Dermatol, Salzburg, Austria
[10] Univ Hosp Essen, Essen, Germany
[11] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
[12] Hannover Med Sch, Skin Canc Ctr, Dept Dermatol & Allergy, Hannover, Germany
[13] Univ Dept Dermatol, Bochum, Germany
[14] Dept Dermatol, Oldenburg, Germany
[15] Univ Dept Dermatol, Munster, Germany
[16] Univ Cologne, D-50931 Cologne, Germany
[17] Dept Dermatol, Dresden, Germany
[18] Univ Dept Dermatol, Ulm, Germany
[19] Dept Dermatol, Darmstadt, Germany
[20] Univ Dept Dermatol, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8505
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408)
    Mohr, P.
    Hauschild, A.
    Enk, A.
    Trefzer, U.
    Rass, K.
    Grabbe, S.
    Brockmeyer, N. H.
    Koller, J.
    Gogas, H.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients
    Weichenthal, Michael
    Chiarion-Sileni, Vanna
    Hauschild, Axel
    Del Bianco, Paola
    Trefzer, Uwe
    Guida, Michele
    Enk, Alexander
    Romanini, Antonella
    Loquai, Carmen
    Ridolfi, Ruggero
    Schadendorf, Dirk
    Mandala, Mario
    Koller, Josef
    Silvestri, Barbara
    Gogas, Helen
    Medici, Michele
    Dummer, Reinhard
    De Salvo, Gian Luca
    Mohr, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]
    Chiarion-Sileni, V.
    Guida, M.
    Romanini, A.
    Ridolfi, R.
    Mandala, M.
    Del Bianco, P.
    Silvestri, B.
    Medici, M.
    Michiara, M.
    Dalla Palma, M.
    Puccetti, O.
    Pigozzo, J.
    Laveder, F.
    De Salvo, G. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Annette
    Schneider, Lars A.
    Podda, Maurizio
    Goeppner, Daniela
    Schadendorf, Dirk
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4077 - +
  • [5] Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b)
    Mohr, P.
    Hauschild, A.
    Rass, K.
    Trefzer, U.
    Enk, A.
    Haalck, T.
    Koller, J.
    Gutzmer, R.
    Kuechler, T.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [7] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [8] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Eggermont, Alexander M. M.
    Bouwhuis, Marna G.
    Kruit, Wim H.
    Testori, Alessandro
    ten Hagen, Timo
    Yver, Antoine
    Xu, Christine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 671 - 677
  • [9] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Alexander M. M. Eggermont
    Marna G. Bouwhuis
    Wim H. Kruit
    Alessandro Testori
    Timo ten Hagen
    Antoine Yver
    Christine Xu
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 65 : 671 - 677
  • [10] A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
    Grignol, Valerie P.
    Olencki, Thomas
    Relekar, Kiran
    Taylor, Cynthia
    Kibler, Amanda
    Kefauver, Cheryl
    Wei, Lai
    Walker, Michael J.
    Chen, Helen X.
    Kendra, Kari
    Carson, William E., III
    [J]. JOURNAL OF IMMUNOTHERAPY, 2011, 34 (06) : 509 - 515
12345